The question of whether only a decrease in Lp(a) results in decreased cardiovascular events will be answered by the study ‘Assessing the Impact of Lipoprotein(a) Lowering with TQJ230 on Major Cardiovascular Events in Patients with Cardiovascular Disease’ (HORIZON; NCT04023552), which will end in 2024. This evidence concerns the gene LPA and cardiovascular disorder.